Notch1 is overexpressed in human intrahepatic cholangiocarcinoma and is associated with its proliferation, invasiveness and sensitivity to 5-fluorouracil in vitro

Oncology Reports

Volumn 31, Issue 6, 2014, Pages 2515-2524

  Wu, Wen Rui ^a   Zhang, Rui ^a   Shi, Xiang De ^a   Zhu, Man Sheng ^a   Xu, Lei Bo ^a   Zeng, Hong ^a   Liu, Chao ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Chemotherapy; Intrahepatic cholangiocarcinoma; Notch1; RNA interference

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; FLUOROURACIL; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; NOTCH1 RECEPTOR; NOTCH1 PROTEIN, HUMAN;

ABCB 1 GENE; ABCG 2 GENE; APOPTOSIS; ARTICLE; BILE DUCT CARCINOMA; BIOASSAY; CANCER CELL; CANCER SIZE; CANCER TISSUE; CELL COUNTING; CELL CULTURE; CELL INVASION; CELL PROLIFERATION; CLINICAL ARTICLE; COLONY FORMATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG MECHANISM; DRUG SENSITIVITY; FEMALE; FLOW CYTOMETRY; GAPDH GENE; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MALE; MRP 1 GENE; NOTCH1 GENE; ONCOGENE; PRIORITY JOURNAL; PROTEIN INTERACTION; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY MECHANISM; RNA INTERFERENCE; WESTERN BLOTTING; AGED; BILE DUCT NEOPLASMS; BIOSYNTHESIS; CELL MOTION; CHOLANGIOCARCINOMA; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; INTRAHEPATIC BILE DUCT; MIDDLE AGED; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR INVASION;

AGED; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CELL MOVEMENT; CELL PROLIFERATION; CHOLANGIOCARCINOMA; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; RECEPTOR, NOTCH1; SIGNAL TRANSDUCTION;

EID: 84902180769     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2014.3123     Document Type: Article

References (24)

1. Guglielmi A, Ruzzenente A and Campagnaro T, et al: Intrahepatic cholangiocarcinoma: prognostic factors after surgical resection. World J Surg 33: 1247-1254, 2009.
2. Goodman ZD: Neoplasms of the liver. Mod Pathol 20 (Suppl 1): S49-S60, 2007.
3. Halappa VG, Bonekamp S and Corona-Villalobos CP, et al: Intrahepatic cholangiocarcinoma treated with local-regional therapy: quantitative volumetric apparent diffusion coefficient maps for assessment of tumor response. Radiology 264: 285-294, 2012.
4. Poggi G, Amatu A and Montagna B, et al: OEM-TACE: a new therapeutic approach in unresectable intrahepatic cholangiocarcinoma. Cardiovasc Intervent Radiol 32: 1187-1192, 2009.
5. Tan JC, Coburn NG, Baxter NN, Kiss A and Law CH: Surgical management of intrahepatic cholangiocarcinoma - a population-based study. Ann Surg Oncol 15: 600-608, 2008.
6. Thongprasert S: The role of chemotherapy in cholangiocarcinoma. Ann Oncol 16 (Suppl 2): i93-i96, 2005.
7. Liapi E and Geschwind JF: Chemoembolization for primary and metastatic liver cancer. Cancer J 16: 156-162, 2010.
8. Dumont AG, Yang Y, Reynoso D, Katz D, Trent JC and Hughes DP: Anti-tumor effects of the Notch pathway in gastro-intestinal stromal tumors. Carcinogenesis 33: 1674-1683, 2012.
9. Brennan K and Clarke RB: Combining Notch inhibition with current therapies for breast cancer treatment. Ther Adv Med Oncol 5: 17-24, 2013.
10. Jonusiene V, Sasnauskiene A and Lachej N, et al: Down-regulated expression of Notch signaling molecules in human endometrial cancer. Med Oncol 30: 438, 2013.
11. Zhu H, Zhou X, Redfield S, Lewin J and Miele L: Elevated Jagged-1 and Notch-1 expression in high grade and metastatic prostate cancers. Am J Transl Res 5: 368-378, 2013.
12. Yu S, Zhang R, Liu F, Wang H, Wu J and Wang Y: Notch inhibition suppresses nasopharyngeal carcinoma by depleting cancer stem-like side population cells. Oncol Rep 28: 561-566, 2012.
13. Villanueva A, Alsinet C and Yanger K, et al: Notch signaling is activated in human hepatocellular carcinoma and induces tumor formation in mice. Gastroenterology 143: 1660-1669, 2012.
14. Yabuuchi S, Pai SG and Campbell NR, et al: Notch signaling pathway targeted therapy suppresses tumor progression and metastatic spread in pancreatic cancer. Cancer Lett 335: 41-51, 2013.
15. Ye QF, Zhang YC, Peng XQ, Long Z, Ming YZ and He LY: siRNA-mediated silencing of Notch-1 enhances docetaxel induced mitotic arrest and apoptosis in prostate cancer cells. Asian Pac J Cancer Prev 13: 2485-2489, 2012.
16. Yoon HA, Noh MH and Kim BG, et al: Clinicopathological significance of altered Notch signaling in extrahepatic cholangiocarcinoma and gallbladder carcinoma. World J Gastroenterol 17: 4023-4030, 2011.
17. Munoz M, Henderson M, Haber M and Norris M: Role of the MRP1/ABCC1 multidrug transporter protein in cancer. IUBMB Life 59: 752-757, 2007. (Pubitemid 351412076)
18. Baguley BC: Multidrug resistance in cancer. Methods Mol Biol 596: 1-14, 2010.
19. Shao H, Huang Q and Liu ZJ: Targeting Notch signaling for cancer therapeutic intervention. Adv Pharmacol 65: 191-234, 2012.
20. Wang M, Xue L and Cao Q, et al: Expression of Notch1, Jagged1 and β-catenin and their clinicopathological significance in hepatocellular carcinoma. Neoplasma 56: 533-541, 2009.
21. Trehanpati N, Shrivastav S and Shivakumar B, et al: Analysis of Notch and TGF-β signaling expression in different stages of disease progression during hepatitis B virus infection. Clin Transl Gastroenterol 3: e23, 2012.
22. Pei J, Tang Z, Zang G and Yu Y: Blockage of Notch1 signaling modulates the T-helper (Th)1/Th2 cell balance in chronic hepatitis B patients. Hepatol Res 40: 799-805, 2010.
23. Nefedova Y, Cheng P, Alsina M, Dalton WS and Gabrilovich DI: Involvement of Notch-1 signaling in bone marrow stroma-mediated de novo drug resistance of myeloma and other malignant lymphoid cell lines. Blood 103: 3503-3510, 2004. (Pubitemid 38525684)
24. Zou J, Li P and Lu F, et al: Notch1 is required for hypoxia-induced proliferation, invasion and chemoresistance of T-cell acute lymphoblastic leukemia cells. J Hematol Oncol 6: 3, 2013.